We are pleased to announce that Atara will be presenting new #SLE and #MS preclinical data today for our investigational CD19 #allogeneic #CART therapy, ATA3219, at the International Society for Cell & Gene Therapy 2024 Annual Meeting in Vancouver, Canada. Read all the details here: https://bit.ly/3yzWrKO
Atara Biotherapeutics’ Post
More Relevant Posts
-
Heading to #ATW24 this year? Let’s discuss how we can partner to simplify your cell and gene therapy research and manufacturing processes by providing the consistency, scalability, and automation you need to streamline your path to commercialization. #advancedtherapiesweek
To view or add a comment, sign in
-
What are the critical factors that influence preclinical cell and gene therapy timelines? What should you look for in a lab partner to expedite your preclinical development? Hear from our subject matter experts to learn more: http://spr.ly/6047VjdPh #CellandGeneTherapy #CellTherapy #GeneTherapy #qPCR
To view or add a comment, sign in
-
Neurogene Expands Low-Dose Cohort of Rett Syndrome Gene Therapy Trial, Adds High-Dose Cohort. The first and second cohorts of the Phase I/II trial of the experimental therapy NGN-401 will enroll patients in parallel with one another. http://ow.ly/NxHL105kCvs
To view or add a comment, sign in
-
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies. ExCellerate GMP iPSC Expansion Medium is optimized to support robust expansion and maintenance of stem cell culture for enhanced consistency and reproducibility throughout the stem cell manufacturing process. The recently released GMP medium complements Bio-Techne's industry leading regenerative medicine therapy workflow solutions, which includes the widest range of GMP cytokines and growth factors available on the market. The ready-to-use media is manufactured without the use of animal components and is available in preclinical and GMP grades to simplify transition from research to clinic. Learn more about ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP) here: https://lnkd.in/ePdmd7Vp #gmp #animalfree #cellandgenetherapy #ipsc
Heading to #ATW24 this year? Let’s discuss how we can partner to simplify your cell and gene therapy research and manufacturing processes by providing the consistency, scalability, and automation you need to streamline your path to commercialization. #advancedtherapiesweek
Schedule an In-person Meeting!
bio-techne.com
To view or add a comment, sign in
-
Let's connect at #ISCT2024! Join our panel discussion on current state and future directions of process analytical technologies. We're elevating your process with cell collections, cell expansion, and fill-finish. Looking forward to seeing you there. #CellandGeneTherapy #CGT ISCT, International Society for Cell & Gene Therapy
To view or add a comment, sign in
-
We’re investing in innovation by supporting #cellandgenetherapy for therapy developers, providers, and patients who may benefit from this promising field. The rapid growth of the cell and gene therapy (CGT) sector is revolutionizing disease treatment, but patients often face unique challenges in accessing these transformative therapies. Watch our free webinar featuring experts from Cencora and our partner, TrakCel Together, we explore the obstacles patients encounter when seeking CGTs and share invaluable insights from commercialization experiences that underscore the significance of wrap-around services for patient support. https://ow.ly/rAGA50SksSC
Streamlining Patient Access to Cell and Gene Therapies
amerisourcebergen.com
To view or add a comment, sign in
-
Launching revolutionary cell and gene therapies (CGT) from lab to patient is a complex but rewarding challenge. 🧬💡 Understanding the BLA filing process and navigating clinical trials are pivotal steps in this quest. 🔍 Dive into the key considerations for BLA filing, ensuring your groundbreaking CGT advancements are set for success. It explains the complexities and breakthroughs in cell and gene therapy development. Ready to learn more? Click the link here ➡️ https://lnkd.in/dc-dqA-Q Have questions about navigating clinical trials? 🤔 LaSalle Group is here to help! #CellGeneTherapy #ClinicalTrials #BiotechInnovation #HealthcareProgress
To view or add a comment, sign in
-
⚛️ Cell and gene therapy is primed to have a big year in 2024, and here is a collection of interesting predictions prepared by Mass General Brigham. Unsurprisingly, there is a clear focus on FDA approval and ensuring safety for future participants. As we have seen in other pieces on similar topics though, paramount to the success of these therapies is not only ensuring that they are indeed safe, but also educating patients and healthcare providers to the extent they feel confident about their safety. #celltherapy #genetherapy #crispr #genomics https://hubs.ly/Q02f2Klp0
2024 Predictions about Gene and Cell Therapy | Mass General Brigham
massgeneralbrigham.org
To view or add a comment, sign in
-
Success in Cell and Gene Therapy trials requires expertise, precision, and a global reach. Read our Case Study to learn how Emmes guided a complex, breakthrough Cell Therapy clinical trial spanning 55 sites in 10 countries, overcoming regulatory hurdles and delivering life-changing therapies. #CellTherapy #ClinicalTrials #GlobalResearch #ClinicalResearch #CRO #CellandGeneTherapy #Emmes
To view or add a comment, sign in
-
Immune rejection is a major drawback with any cell therapy. One way to overcome this is to interfere with the immune recognition properties of the therapeutic cell by gene editing. For example, the HLA 1 system can be modulated by knocking out the B2M gene, which controls recognition of the therapeutic cell by the immune system. To find out how our StemEdit Clinical Gene Editing can help your project: https://hubs.li/Q02mPY8W0
To view or add a comment, sign in
37,096 followers